Cipla's oseltamivir supply plans to re-ignite access debate
This article was originally published in Scrip
Executive Summary
Cipla's plans to supply a generic version of Roche's Tamiflu (oseltamivir) to Mexico are expected to re-ignite debate over patents and access to medicines.